ClinicalTrials.gg
RecruitingNCT06759545Updated Feb 6, 2025

An Interventional Pilot Study on the Effect of Extra Virgin Olive Oil on Women with Preeclampsia Risk

An interventional study of Dietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH and Dietary MOH recommendations in Preeclampsia (PE) Risk, sponsored by Yaniv Ovadia. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Yaniv Ovadia · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Pre-Eclampsia with a site in Israel — 3 open to participants now, 3 under way, none of them phase 3. Pre-Eclampsia · Israel.

Planned enrollment
2nd of 10
156 · median 60
Started
2025
the only one that year
No phase
5 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies in Pre-Eclampsia with a site in Israel, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 5 with no phase, and was the 27th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

3 of the 28 studies in Pre-Eclampsia with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pre-Eclampsia with a site in Israel, or all of them as a file.
02

Study summary

This study explores the potential benefits of Extra Virgin Olive Oil from early harvested olives (EVOOEH) in reducing the risk of preeclampsia (PE) in high-risk pregnant women. EVOO, particularly EVOOEH, is rich in antioxidant compounds, including polyphenols, which may help improve vascular health and reduce oxidative stress, potentially preventing complications like PE. The hypothesis is that EVOOEH may reduce microvascular damage, improve placentation, and prevent dysglycemia, ultimately lowering the risk of PE and gestational diabetes mellitus (GDM).

The primary objective of this intervention is to evaluate the effect of EVOOEH on PE incidence during pregnancy, specifically assessing the impact on markers of PE, GDM, and other pregnancy-related outcomes. The study is designed as an interventional, randomized, parallel-assignment dietary trial involving 156 pregnant women at high risk for PE, aged 18 to 45. Participants will receive either a daily dose of 42 ml (three tablespoons) of EVOOEH or the Ministry of Health (MOH) general dietary recommendations for pregnancy for four weeks, starting between 8 to 16 weeks of gestation.

The study arms are as follows:

EVOOEH arm: Participants will consume 42 ml of EVOOEH daily along with MOH dietary recommendations for four weeks (n=78).

Control arm: Participants will follow only the MOH dietary recommendations for four weeks (n=78).

The intervention will occur alongside low-dose aspirin prophylaxis for PE prevention, as recommended by guidelines for women at high risk. Key compliance markers include adherence to a Mediterranean diet as measured by the Mediterranean Diet Adherence Screener (MEDASIS) and hydroxytyrosol levels in maternal blood. The study will mask data analysis to minimize bias.

The primary outcome measures are maternal glucose challenge test (GCT) results and the serum soluble FMS-like tyrosine kinase 1/placental growth factor (sFlt-1/PlGF) ratio at the end of the intervention. Secondary outcomes include the incidence of GDM, PE, cesarean sections, preterm delivery, small for gestational age (SGA) births, blood pressure measurements, gestational age at delivery, and any relevant data available from participants' medical records.

Eligibility criteria include pregnant women with risk factors for PE such as a history of PE, chronic hypertension, obesity, or diabetes, among others, and a gestational age between 8 to 16 weeks. Exclusion criteria involve low-risk pregnancies or women who refuse participation.

Blood samples will be collected to assess 25-hydroxyvitamin D (25(OH)D), hydroxytyrosol (HT), and the sFlt-1/PlGF ratio. Laboratory analyses will be conducted at Barzilai University Medical Center and the Weizmann Institute of Science. This study seeks to determine whether EVOOEH's higher polyphenol content compared to standard EVOO can offer additional protective benefits against PE and related complications in high-risk pregnancies.

03

Conditions studied

  • Preeclampsia (PE) Risk

Browse trials for

Keywords

  • Extra virgin olive oil from early harvested olives
  • preeclampsia
  • FMS-like tyrosine kinase 1
  • plasma hydroxytyrosol
  • dietary intervention
  • point Mediterranean Diet Adherence Screener
  • prevention
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with clinical risk factors for PE [previous PE, primigravida, chronic hypertension, chronic renal disease, disease (systemic lupus erythematosus, antiphospholipid antibody syndrome), overweight (>30), obesity (BMI>35), morbid obesity (BMI>40), presentational diabetes (type 1 or type 2), multiple pregnancy].
  • gestational ages of 8 to 16 weeks attending Barzilai University Medical Center at Ashkelon (BUMCA).

Exclusion criteria

Exclusion Criteria:

  • Refusing enrollment or participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    EVOOEH arm

    Daily addition of 42 ml (three tablespoon) at each morning of EVOOEH to MOH recommendations for 4 weeks (n=78).

    Other: Dietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH

  • Other
    Control arm

    MOH recommendations for 4 weeks (n=78).

    Other: Dietary MOH recommendations

Interventions

  • OtherDietary MOH recommendations and daily addition of 42 ml (three tablespoon) at each morning of EVOOEH

    Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) with addition of three tablespoon (42 ml) EVOOEH (up to 0.8% free acidity) per day at each morning for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)

  • OtherDietary MOH recommendations

    Dietary intervention study: high-risk pregnant women receiving a link to MOH general dietary recommendations for pregnancy (MOH recommendations) for four weeks during the first half of pregnancy (gestational ages between 8 to 16 weeks)

06

What researchers measure

Primary outcomes

  1. sFlt-1/PlGF ratio

    Post intervention serum sFlt-1/PlGF ratio at the end of intervention.

    Time frame: 4 weeks

  2. GCT result

    Post intervention maternal GCT result at the end of intervention.

    Time frame: 4 weeks

Secondary outcomes

  1. SBP

    Maternal systolic diastolic blood pressure

    Time frame: At recruitment and approximately 4 weeks post intervention initiation

  2. DBP

    Maternal diastolic diastolic blood pressure

    Time frame: At recruitment and approximately 4 weeks post intervention initiation

  3. PE

    PE diagnosis

    Time frame: From intervention to delivery

  4. GDM

    GDM diagnosis

    Time frame: From intervention to delivery

  5. CS

    Cesarean section incidence

    Time frame: At delivery

  6. Preterm

    Preterm incidence

    Time frame: At birth

  7. SGA

    SGA incidence

    Time frame: At birth

  8. Birthweight percentile

    Newborn adjusted with percentile

    Time frame: At birth

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 6, 2025
StartActual
Jan 28, 2025
Primary completionEst.
Jan 7, 2027
CompletionEst.
Jan 7, 2028
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06759545
Lead sponsor
Yaniv Ovadia
Responsible party
Yaniv Ovadia (Dr Yaniv S. Ovadia RD PhD, Barzilai Medical Center) — Sponsor-investigator
First posted
Jan 6, 2025
Start date
Jan 28, 2025
Primary completion
Jan 7, 2027 (estimated)
Completion
Jan 7, 2028 (estimated)
Last update
Feb 6, 2025

Study contacts

Yaniv Dr Yaniv S. Ovadia, RD PhD
Contact
yaniv.ovadia@mail.huji.ac.il
+ 972 8 6745220
Arie Dr Arie Budovsky, PhD
Contact
arieb@bmc.gov.il
+ 972 8 6746146
Dr Yaniv S. Ovadia, RD PhD
study director · Barzilai University Medical Center Ashkelon

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion